Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia

Pharmacogenomics

Volumn 14, Issue 1, 2013, Pages 25-34

  Hu, Miao ^a   Mak, Valiant W L ^a   Xiao, Yajie ^a   Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CYP3A; pharmacogenetics; polymorphism; PPARA; simvastatin

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ADENINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GUANINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CHINESE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIET RESTRICTION; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; PATIENT COMPLIANCE; REGULATOR GENE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINE LEVEL;

ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; HYDROCORTISONE; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SIMVASTATIN; TRIGLYCERIDES;

EID: 84871453438     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.181     Document Type: Article

References (53)

1. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670-1681 (2010).
2. Hu M, Mak VWL, Chu TTY, Waye MMY, Tomlinson B. Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Curr. Pharmacogenomics Pers. Med. 7(1), 1-26 (2009).
3. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab. Dispos. 18(2), 138-145 (1990). (Pubitemid 20107705)
4. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41(5), 343-370 (2002). (Pubitemid 34713089)
5. Prueksaritanont T, Gorham LM, Ma B et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. 25(10), 1191-1199 (1997). (Pubitemid 27446590)
6. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
7. Elens L, Becker ML, Haufroid V et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam study. Pharmacogenet. Genomics 21(12), 861-866 (2011).
8. Kivisto KT, Niemi M, Schaeffeler E et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14(8), 523-525 (2004). (Pubitemid 39100004)
9. Li YP, Zhang LR, Jia M, Hu XJ. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J. Clin. Pharmacol. 51(2), 181-188 (2011).
10. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001). (Pubitemid 32385908)
11. Ozdemir V, Kalow W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10(5), 373-388 (2000). (Pubitemid 30433571)
12. Klein K, Thomas M, Winter S et al. PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo. Clin. Pharmacol. Ther. 91(6), 1044-1052 (2012).
13. Hustert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9), 773-779 (2001). (Pubitemid 33151512)
14. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 47(1), 87-93 (2007).
15. Thompson JF, Man M, Johnson KJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5(6), 352-358 (2005).
16. Fiegenbaum M, Da Silveira FR, Van Der Sand CR et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78(5), 551-558 (2005). (Pubitemid 41698910)
17. Willrich MA, Hirata MH, Genvigir FD et al. CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin. Chim. Acta 398(1-2), 15-20 (2008).
18. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14(1), 1-18 (2004). (Pubitemid 38183957)
19. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001). (Pubitemid 32268418)
20. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87(1), 130-133 (2010).
21. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
22. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16(12), 873-879 (2006). (Pubitemid 44772805)
23. Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 10(1), 1-11 (2009).
24. Hu M, Mak VW, Tomlinson B. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet. Genomics 22(11), 803-806 (2012).
25. Park BK. Assessment of urinary 6b-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br. J. Clin. Pharmacol. 12(2), 97-102 (1981). (Pubitemid 11034426)
26. Furuta T, Suzuki A, Mori C, Shibasaki H, Yokokawa A, Kasuya Y. Evidence for the validity of cortisol 6b-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab. Dispos. 31(11), 1283-1287 (2003). (Pubitemid 37310312)
27. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18(6), 499-502 (1972).
29. Xiao YJ, Chan SW, Hu M et al. Simultaneous determination of cortisol, cortisone, and 6b-hydroxycortisol in human urine using ultra performance liquid chromatography coupled with UV detector. Chromatographia 75(3), 169-173 (2012).
30. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005). (Pubitemid 40202029)
31. Purcell S, Cherny SS, Sham PC. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19(1), 149-150 (2003). (Pubitemid 36150192)
32. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 34(11-12), 961-971 (2004). (Pubitemid 40070099)
33. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol. 84(7), 811-815 (1999). (Pubitemid 29469791)
34. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin. Pharmacol. Ther. 67(3), 267-274 (2000). (Pubitemid 30176385)
35. You JH, Chan WK, Chung PF, Hu M, Tomlinson B. Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects. J. Clin. Pharmacol. 50(10), 1151-1158 (2010).
36. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur. J. Clin. Pharmacol. 64(9), 877-882 (2008).
37. Zhang W, Chang YZ, Kan QC et al. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur. J. Clin. Pharmacol. 66(1), 61-66 (2010).
38. Miura M, Satoh S, Kagaya H et al. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12(7), 977-984 (2011).
39. Chew SC, Singh O, Chen X et al. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother. Pharmacol. 67(6), 1471-1478 (2011).
40. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. 93(1), 104-107 (2004). (Pubitemid 38022047)
41. Gordon RY, Becker DJ, Rader DJ. Reduced efficacy of rosuvastatin by St. John's Wort. Am. J. Med. 122(2), e1-e2 (2009).
42. Peng CC, Templeton I, Thummel KE, Davis C, Kunze KL, Isoherranen N. Evaluation of 6b-hydroxycortisol, 6b-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin. Pharmacol. Ther. 89(6), 888-895 (2011).
43. Grogan WM, Phillips VM, Schuetz EG, Guzelian PS, Watlington CO. Corticosterone 6b-hydroxylase in A6 epithelia: a steroid-inducible cytochrome P-450. Am. J. Physiol. 258(3 Pt 1), C480-C488 (1990). (Pubitemid 20118943)
44. Li D, Abudula A, Abulahake M, Zhu AP, Lou YQ, Zhang GL. Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6b-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese. J. Clin. Pharmacol. 50(7), 775-784 (2010).
45. Diczfalusy U, Miura J, Roh HK et al. 4b-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet. Genomics 18(3), 201-208 (2008). (Pubitemid 351323234)
46. Chen YC, Gotzkowsky SK, Nafziger AN et al. Poor correlation between 6b-hydroxycortisol: cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. Br. J. Clin. Pharmacol. 62(2), 187-195 (2006). (Pubitemid 44316429)
47. Diczfalusy U, Nylen H, Elander P, Bertilsson L. 4b-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br. J. Clin. Pharmacol. 71(2), 183-189 (2011).
48. Lutjohann D, Marinova M, Schneider B et al. 4b-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo-effects of itraconazole in man. Int. J. Clin. Pharmacol. Ther. 47(12), 709-715 (2009).
49. Benet LZ. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol. Interv. 5(2), 79-83 (2005). (Pubitemid 40590507)
50. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47(5), 566-578 (2007). (Pubitemid 46632158)
51. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 10(6), 1017-1024 (2009).
52. Feidt DM, Klein K, Hofmann U et al. Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes. Drug Metab. Dispos. 38(9), 1589-1597 (2010).
53. Kokudai M, Inui N, Takeuchi K, Sakaeda T, Kagawa Y, Watanabe H. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. J. Clin. Pharmacol. 49(5), 568-573 (2009).